• 1
    Zurlo F, Larson K, Bogardus C. et al. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest. 1990;86:14231427.
  • 2
    DeFronzo RA, Gunnarsson R, Bjorkman O. et al. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest. 1985;76:149155.
  • 3
    Baron AD, Brechtel G, Wallace P, et al. Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol. 1988;255:E769E774.
  • 4
    Ekelund U, Brage S, Franks PW. et al. Physical activity energy expenditure predicts progression toward the metabolic syndrome independently of aerobic fitness in middle-aged healthy Caucasians: the Medical Research Council Ely Study. Diabetes Care. 2005;28:11951200.
  • 5
    Rennie KL, McCarthy N, Yazdgerdi S. et al. Association of the metabolic syndrome with both vigorous and moderate physical activity. Int J Epidemiol. 2003;32:600606.
  • 6
    Kelley DE, Goodpaster B, Wing RR, et al. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol. 1999;277:E1130E1141.
  • 7
    Ishiki M, Klip A. Minireview: recent developments in the regulation of glucose transporter-4 traffic: new signals, locations, and partners. Endocrinology. 2005;146:50715078.
  • 8
    Bjornholm M, Zierath JR. Insulin signal transduction in human skeletal muscle: identifying the defects in type II diabetes. Biochem Soc Trans. 2005;33:354357.
  • 9
    Krook A, Wallberg-Henriksson H, Zierath JR. Sending the signal: molecular mechanisms regulating glucose uptake. Med Sci Sports Exerc. 2004;36:12121217.
  • 10
    Kiens B. Skeletal muscle lipid metabolism in exercise and insulin resistance. Physiol Rev. 2006;86:205243.
  • 11
    Brehm A, Krssak M, Schmid AI, et al. Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. Diabetes. 2006;55:136140.
  • 12
    Stump CS, Short KR, Bigelow ML. et al. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci U S A. 2003;100:79968001.
  • 13
    Kelley DE. Skeletal muscle fat oxidation: timing and flexibility are everything. J Clin Invest. 2005;115:16991702.
  • 14
    Storlien L, Oakes ND, Kelley DE. Metabolic flexibility. Proc Nutr Soc. 2004;63:363368.
  • 15
    Sloniger JA, Saengsirisuwan V, Diehl CJ, et al. Defective insulin signaling in skeletal muscle of the hypertensive TG(mREN2)27 rat. Am J Physiol Endocrinol Metab. 2005;288: E1074E1081.
  • 16
    Brozinick JT Jr, Roberts BR, Dohm GL. Defective signaling through Akt-2 and -3 but not Akt-1 in insulin-resistant human skeletal muscle: potential role in insulin resistance. Diabetes. 2003;52:935941.
  • 17
    Kim YB, Kotani K, Ciaraldi TP, et al. Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes. 2003;52:19351942.
  • 18
    Henriksen EJ, Jacob S, Kinnick TR. et al. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension. 2001;38:884890.
  • 19
    Kelley DE, Mintun MA, Watkins SC. et al. The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest. 1996;97:27052713.
  • 20
    Blendea MC, Jacobs D, Stump CS, et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab. 2005;288:E353E359.
  • 21
    Baron AD, Zhu JS, Marshall S, et al. Insulin resistance after hypertension induced by the nitric oxide synthesis inhibitor L-NMMA in rats. Am J Physiol. 1995;269:E709E715.
  • 22
    Duplain H, Burcelin R, Sartori C. et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001;104:342345.
  • 23
    Puato M, Faggin E, Favaretto E. et al. Prevalence of fetal-type smooth muscle cells in the media of microvessels from hypertensive patients. Hypertension. 2004;44:191194.
  • 24
    Frisbee JC. Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol. 2005;289: R307R316.
  • 25
    Vogt CJ, Schmid-Schonbein GW. Microvascular endothelial cell death and rarefaction in the glucocorticoid-induced hypertensive rat. Microcirculation. 2001;8:129139.
  • 26
    Ogihara T, Asano T, Ando K. et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension. 2002;40:872879.
  • 27
    Morino K, Petersen KF, Dufour S, et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest. 2005;115:35873593.
  • 28
    Huang X, Eriksson KF, Vaag A, et al. Insulin-regulated mitochondrial gene expression is associated with glucose flux in human skeletal muscle. Diabetes. 1999;48:15081514.
  • 29
    Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307:384387.
  • 30
    Petersen KF, Dufour S, Befroy D. et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350:664671.
  • 31
    Hernandez N, Torres SH, Vera O. et al. Muscle fiber composition and capillarization in relation to metabolic alterations in hypertensive men. J Med. 2001;32:6782.
  • 32
    Montani JP, Carroll JF, Dwyer TM, et al. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int J Obes Relat Metab Disord. 2004;28(suppl 4):S58S65.
  • 33
    Schrauwen P, Hesselink MK. Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes. 2004;53:14121417.
  • 34
    Houmard JA, Tanner CJ, Yu C. et al. Effect of weight loss on insulin sensitivity and intramuscular long-chain fatty acyl-CoAs in morbidly obese subjects. Diabetes. 2002;51:29592963.
  • 35
    Cree MG, Newcomer BR, Katsanos CS. et al. Intramuscular and liver triglycerides are increased in the elderly. J Clin Endocrinol Metab. 2004;89:38643871.
  • 36
    Roden M, Price TB, Perseghin G. et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996;97:28592865.
  • 37
    Yu C, Chen Y, Cline GW. et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem. 2002;277:5023050236.
  • 38
    Goodpaster BH, He J, Watkins S. et al. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab. 2001;86:57555761.
  • 39
    Ritov VB, Menshikova EV, He J. et al. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes. 2005;54:814.
  • 40
    Wisloff U, Najjar SM, Ellingsen O. et al. Cardiovascular risk factors emerge after artificial selection for low aerobic capacity. Science. 2005;307:418420.
  • 41
    He J, Kelley DE. Muscle glycogen content in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2004;287:E1002E1007.
  • 42
    Lillioja S, Young AA, Culter CL. et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest. 1987;80:415424.
  • 43
    Saengsirisuwan V, Perez FR, Sloniger JA, et al. Interactions of exercise training and alpha-lipoic acid on insulin signaling in skeletal muscle of obese Zucker rats. Am J Physiol Endocrinol Metab. 2004;287:E529E536.
  • 44
    Shiuchi T, Iwai M, Li HS. et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension. 2004;43:10031010.
  • 45
    Ogihara T, Asano T, Katagiri H. et al. Oxidative stress induces insulin resistance by activating the nuclear factor-kappa B pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase. Diabetologia. 2004;47:794805.
  • 46
    Sugita H, Fujimoto M, Yasukawa T. et al. Inducible nitric-oxide synthase and NO donor induce insulin receptor substrate-1 degradation in skeletal muscle cells. J Biol Chem. 2005;280:1420314211.
  • 47
    MacLellan JD, Gerrits MF, Gowing A, et al. Physiological increases in uncoupling protein 3 augment fatty acid oxidation and decrease reactive oxygen species production without uncoupling respiration in muscle cells. Diabetes. 2005;54:23432350.
  • 48
    Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004;286:H1597H1602.
  • 49
    Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:11111119.
  • 50
    Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord. 2003;27(suppl 3):S53S55.
  • 51
    Plomgaard P, Bouzakri K, Krogh-Madsen R, et al. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 2005;54:29392945.
  • 52
    Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439451.
  • 53
    Chen MB, McAinch AJ, Macaulay SL. et al. Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J Clin Endocrinol Metab. 2005;90:36653672.
  • 54
    Roberts CK, Won D, Pruthi S, et al. Effect of a diet and exercise intervention on oxidative stress, inflammation, MMP-9 and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol. December 15, 2005; [Epub ahead of print].
  • 55
    Stewart KJ, Bacher AC, Turner K. et al. Exercise and risk factors associated with metabolic syndrome in older adults. Am J Prev Med. 2005;28:918.
  • 56
    Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98:11541162.
  • 57
    Henriksson J. Effects of physical training on the metabolism of skeletal muscle. Diabetes Care. 1992;15:17011711.
  • 58
    Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr. 2005;25:391406.
  • 59
    Ferrier KE, Nestel P, Taylor A. et al. Diet but not aerobic exercise training reduces skeletal muscle TNF-alpha in overweight humans. Diabetologia. 2004;47:630637.
  • 60
    Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab. 2004;30:498505.
  • 61
    Miyazaki Y, He H, Mandarino LJ. et al. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes. 2003;52:19431950.
  • 62
    Stump CS, Clark SE, Sowers JR. Oxidative stress in insulin-resistant conditions: cardiovascular implications. Treat Endocrinol. 2005;4:343351.